CD28 and B-cell non-Hodgkin lymphoma: In the most direct human comparison to date, Ramos et al. conducted a first-in-human, within-patient comparison of second-generation (CD28-only) versus third-generation (CD28 + 4-1BB) CD19-specific CAR-T products in patients with R/R B cell non-Hodgkin lymphoma.